Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, and what-not has predictably returned. There is only one solution to this challenge: a few cups of stimulation. We are relying on cinnamon dolce and, as always, invite you to join us. Remember, no prescription is required. So no copay accumulators are involved. Meanwhile, here are some tidbits. Have a smashing day and do keep in touch …
Some of the largest Allergan (AGN) shareholders have approached potential activist investors to gauge their interest in pushing for change at the drug maker, Business Insider reports. A number of funds with top 50 positions say they have held talks with Allergan over the last several months about selling off businesses that are not central to its strategy, such as women’s health, urology, and gastroenterology. They argue the focus should be on the core aesthetics business. The funds also encouraged the activists to build a stake in Allergan to press management to change its strategy faster.
About the Author Reprints
